Edgewise Therapeutics Completes Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline

Edgewise Therapeutics, Inc. has finalized the sale of its muscular dystrophy business and the drug sevasemten to French pharmaceutical company Servier for a total consideration of up to $2.65 billion. The transaction, which was completed on July 13, 2026, includes an upfront cash payment of $1.55 billion, with an additional potential $1.1 billion tied to regulatory and commercial milestones. This strategic move is designed to bolster Edgewise's financial standing while allowing it to concentrate on its cardiovascular pipeline.

Edgewise Therapeutics, based in Boulder, Colorado, is a clinical-stage biopharmaceutical company focused on developing therapies for cardiovascular diseases. With the completion of this transaction, Edgewise is poised to transition into a company primarily dedicated to cardiovascular treatments, including its lead candidate, EDG-7500, which targets hypertrophic cardiomyopathy. The upfront cash proceeds from the sale are expected to fully fund the development of EDG-7500 through to potential approval, thereby enhancing the company’s financial flexibility.

Servier, an independent international pharmaceutical group, is acquiring sevasemten, which is currently in late-stage clinical trials for Becker and Duchenne muscular dystrophy. This acquisition aligns with Servier's strategic goals to expand its portfolio in rare diseases and neurology, particularly as it aims to become a significant player in the rare neurology sector by 2030. The deal not only brings sevasemten's promising therapeutic potential under Servier's umbrella but also includes the transfer of key intellectual property, regulatory filings, and clinical data necessary for the continued development of the muscular dystrophy business.

The muscular dystrophy market is characterized by a growing demand for innovative therapies, particularly for conditions like Becker and Duchenne muscular dystrophy, which currently lack effective treatment options. Sevasemten has shown promise in clinical studies, demonstrating sustained disease stabilization and a favorable safety profile. With regulatory designations such as FDA Orphan Drug Designation and EMA Orphan Drug Designations, sevasemten is positioned to address significant unmet medical needs in the muscular dystrophy space.

The completion of this transaction signals a broader trend in the biopharmaceutical sector, where companies are increasingly focusing their resources on core therapeutic areas. As Edgewise shifts its focus to cardiovascular diseases, it reflects a strategic realignment that many biopharmaceutical firms are undertaking to optimize their pipelines and enhance shareholder value. The successful integration of sevasemten into Servier's portfolio could accelerate the development of new treatment options for patients with rare neuromuscular conditions, ultimately contributing to advancements in the field.